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onmlllntty-acquired lower r 'spiraeory cr. et infections are rill a
m3Jor canw of death world-\V1de, occupylllg fW,it place among
1I11~CCl0ll5 ,hsea'ie as a sII1g1c cause ofdeath [I]. The 111 rtahty rate
lor th\'Se II1ft<cC!o!lS III adults ranges from 1')1,,....2% In a~es treated;1{
hOIl1<: to 5lJ% r those adnucu:d to intenSIVe c rc urnes [21,
The mortahty. particularly in t:lderly subjects, also depcnru.
on the p;nhogen involved, ranging from 20% in cases of
pneumococcal enology to 33% in the presence of Gram-
Ill:gilove ITIJcroorganiS111s.
TIle enology 15 mulaple and the eool0!9c.'ll diagnosis po '\"S
scnoll5 problems O\V1ng to difficulties in btallling valid biological
<;;\lnpl "1lhout resomJlg t I lnv:l~iVl: te hmqu' , which cannOl
bc ll.'cd in the home etring. a.. well J5 to potential cont;lI~lination
of rnc m;l{cnal hy the nucroblal II ra of the or.1I C:1V1ty.
TheraI' . in this context, is aJm t invariably empirical and
has to he based on the knowledge of the etiological agents,
wluch vary In rdatlon to the patient's age nd. parocularly
today, to knowledge of the epldemtOlogy of ba teri~l
,lJ,St;cptlblliry .111<1 fc\i~tancc nn a narional or local sca.lc.
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The nllcro rg;tni<m, llIosr [fe:cluentl involved in tht:se
infections arc. fn'I'fIJ(o(nlS /HlCIiI/lOlljfll'. H(/I'I//opllillls iI!f'l1cI/zt1l·.
MyropltwlI<I P"CIiI/lIJ/IlIIl" CII1f1l/lyrlill IIIII.'II"","i<ll'. ugiolll'lIo spp.,
KIt·bsil·1I11 pm'//IIIOllifll' Jnd Olha Gram-ncg:tovl.'s. rhe l:mer
being dctl.'cted parowl. rly In the elderly.
The drug:; t be used in the empirical or r.ltlon~l th..·r.lPY ofsuch
mfectiolls obviously have to be active against th\'Se pathogens.
Seriou problems ~V1th both . /rI'l'foroallS PIICHlllV1li1l1! ,nd
HI/CllflIp/li/lls i"jllll'IrzfI/' have ell1erged over fceem years in ITlany
countncs throughout the world. The findings of the Alexander
Project able I) (3J ~h w thar, In IrC/lIorV(rtlS pllel",lIl1/i",', the
incidence of penicillin t..~stance may be as high :lS JO'Y<r-40%
in the USA and some European countries ( pain, FrJnce).
High reSiStallCe rate are also reported for l-/<lc/Mp/li/IlS
j,if/IICIIZIIC' and Morll.vl'1lrl mfllJTlmlis.
In Italy, the simatlon is very diffC'rellt from that 111 the: U A
and In other European counmcs: the re ults of the Epidemio-
logical Ob ervatory 0 the, mith Kline FOLlnd3rion [41 show dlat
the incidence of ,reph'corrrlS }"'I'IlIllV"i<ll' rc istant to I'enidllin L~
very 10\ (3.8% in 19(8) (fable 2). regards HarmllpIJilIls
j'!f1I1CII::IJC. the percentage of 13-lact.1JTL1Sc-producing strains WJ~
5.2% in 1997 and 12.2% 111 1998 (fable: 3). A ~Iight pcrcentage
incre. e III r~ ist:mcc: C<l1T be Jlotcd. though dle r.lrc.< rCIll, in
distincdy lower thJO Lho~e reported III m~ny oUlcr l:ountnc. [5J.
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Table 2 S""II. Kl,ne Founda"on "al,an Observatory percenlllge
SUSl:Cpl'llllily of Sifepto occus I'",wnl()/lloe SI,,"ns I 51 d, 1998
No.
Antibiotic strains S AI %
Ponlclll", 820 873 89 38
Amo",c,'lin 841 949 11 40
AmoxlcllI",·clovul mc aCid 843 958 09 32
CcfUIOXlrHe 802 91 5 24 61
Celotaxon,e 820 945 28 2.7
Celtlloxone 819 4. 23 3'
by,h,omycln 844 682 33 284
Clalllh,omycII' 841 71 7 20 263
All IIIfOlllyC111 843 74 3 18 240
COIr"nox,17ol 820 693 18.9 '18
T uacyclill S 842 682 26 29.2
It I' Lw no I1\l',lIl' C.ISV [0 undasr,lnd rI'l' re~,nns for the'c
'1IIht.lI11t.1I dll l'relll'e' III 'u ccpnhllll ' p,urcrIIs hcrwcen thc
I',trlml' II, UOIl'. The mO'1 obv\Ou' l'Xpl.lIl, lion h,ls (0 do
wlrh thc ddl\:rcllI WJy' .,nnbHltl'l Ml' U'l"l. both III lerms of
,ho'''1; ,If d,ug or ,lrII/-: .."l11hll1.II'OI1' ,lIhl III l,'rll1' of
.1dl1lllll\rr,llIOIl roUll"
A r<:l'ctll \IlI'C'U!--':111011 on tho: II"; "f ,1I111biollO 111 thc
trC.llIllCIIl 1lI'Iowcr respll';1[<)ry tr~n Inli:rtlom 161 ,hows thal,
III 1I,Ih,rn hOVltal-, thITe " j d"tII'Cl prdercllcc lor thc
p;'ll'li!l'r,d ntlllC COlllp"rl'd wlrh (11',,1 ,ldlllln"rr,ltilln (H-I VI.
2-1.7%.), l'or ,mgk-drulo: lherJp , (l1Illp,lrl'd wah ('omb,natlol1
therapy (6H.H"n I'S. -' 1.2"Yn), ,1I1l1. ,IboYe all, for the me of P-
laet~nlS (6·tH",,) .mil ,·,'pha!o'ponm (3l-l.'J%) , .lllilOSt .dlV,ly'
rlttrd p;Cller,1tI0n, ,l,hllllllStercd p,lrctHl.'r,llly.
A 'lIll1br. though leIS 111.1 keJ tClidellcv, 1\ ,1\\0 IOlll1d III
Ihe Iher"I'Y of I"wer rC\I',rarorv [",,'t III Il'cflOI1S III till'
COllllllUllity IClflllg' ill thi, ClIllIl')(l. III . drtlV;\ ,Ire Illr ... 1I
.Idlllllml\'lcd 1',lrenrer,llIy III ILlly. 1I1.111t1y 1I1lramll>culariy.
Th\'ll' arc 'q;ndicam dlllerl'llcel III ll>,lge 1',lltern, 111 lI,c
v;.rilll" ""glom 0 Il,lly; In particular. the u\e of pal'elHer.ll
Concia Role of parenteral cephalosponns s\
,11ll.biortC\ III (01l1ll1l111lty l1ledlCIlll' l' very pronoullced III
';ollthc:rll 11.11y.
III l'l'cent yeal\. lhnc has hecn "n Illcrea\lllg tendcncy to
adopt ther.'I"'lltiC gllldcllll'" aITllr,i1ng to Klelllltic c"ldcIlCC-
It.,,...d Lrtten.'. 1.0:. ,m lh ... ha.'I' o( cOlllrolled hmol tnall JlllIe,!
,II 0l'llllllZll1g b,"h t11l'rJpeulIc clIicJ \' dud cOllsumptlon of
h,'al, h-,•• re 1'... " lI! rce,
TI1l' 'ntrodlll nOll of Ill'\\' ,lllablonC'>, allJ. above all.
"I'hlclllllllo~l'al ,i1lll'rcllcl'" .Ill,! l hang... ' III b,t tcn.,1 re\l\t..lllce
p.Ut,...", III;I!;" 1l ab\olmdv Ill,md.,tory 10 l'n!uate th ...
111\... lIanollJI gUlllehlle\ (nnollv ,11lL! re".ew thelll Ircquentlv.
The 1ll,IIn g'lIldcllllC\ 1('1' till' 'r....trIn...1ll o( CIlI11Ullll1ltV-
,\c'IUlr,'d p"ellllll Illd ,lrl' thmc 01 the Inli.-cllom D,sea.,cs
')0 'Il'ty or I1ll.'nC.1 17 J, tho. l' of the ,lllfhonl.ll.ve, IIlJt'pc:ndelll
Jounl.11. 'Orr .III'tllntl Lt'II..,. IHI, dod tho'" ,( the Europ",l11
'tllldy on COll1l1lumry Acqulrcd Pn ...1I1ll0111.1 '0Il111llttee 19/,
Thc AllIen 'an ~lldehu...s ,II1J e),pert' of -n,~ ,\k,I"',,, 1..1.'//("
,l,l"o,'a,,' lhe: lIla.-roltdc:s, the Ilew lluor()'1111ll01()lll~ (ll'"OI]"X-
,Iem) wllh f:olll ,lllll-Sln'}'I(I(,)(jlf) 1""'lmll'III.,~ ,Ktll"ry, (I'
doxy(ydllil' ,1\ tit ... iil'l>l-choi(e ,Iru~
For Ito pital Illp,ltI ... n s they <llggC" lhe u'e "f J P-J.u.:talll
(th,rd-~en ... r,moll ,·ephalo..p"nlll or ~-hh:ral1l pllll ~lactam.l-'e
Inh,b,tor) wllh or wHhom ,1 m~nnltd,', or new tlunroql1lnn-
lone ~Iolle.
For p,ltIellts wah 'cVt'rc: pneunl 111.1. "dnuttc:d t Illrenslvc
":,1fe, thl' lombll1ari n of .1 ~Ia ·tam plm ,I nl.'lCTolidc 1\
relo:ardcd ,IS lh,' rtlO'1 el1c('[I\'l' til'\r-choice therapy
Thl' Europe,ln p;llIddIlIC:', unltke lhose mCllllolle:d
,lbnvc, rccommend ll\,n~ ,11l1lnOpl'IIICdhn\ a\ first-eho'ee
drugs III hOlllc treatment of cOlllmunnv-acqUlrcd pnculllo-
ilia. hc lIIacrohdn, new rluoroqullloioncs and tetr.(\,-
ellll"" Jr" rt'gar led J5 ,llternJuvl' drugs. For ho pltal
Il1pall ... l1ts or p,1uenl' III IlIIe1151\'C care, 011 thc other h. lid,
the Ellr pe.11l ft'C tnll1elldaliO/lS .Ut: the ',Int" ,IS rho.." or lh"
IIlcrtcal1 p:1II'-!chnc5.
Table 3 Percenlege susceptlb,Ii'y. Intermed'ate susccpllb,llIy and ,eslsl~nco 10 various "nllhlo"cs In H. mfluenzae strains Isola'ed In 1997 and 1998
In Ilaly
1997, Hoemoph/lus influonzao (670) 1998, HBontophllus InfluonzBB (608)
Antibiotic %5 %1 %R %5 %1 %A
AmplcllI,n 948 1.2 4.0 878 33 89
Amo.,c,lhn 94,8 1.2 40 87.8 3.3 89
Ce'eclol 99.0 02 08 96.2 13 25
Colurox,mo 100 970 12 18
AZ,lhromyclll 987 1 3 967 3.3
Ciall'hromycill 89.6 73 37 799 161 5.0
Chlo,omphomcol 973 1.0 1 7 97.9 13 0.8
Colflmoxazoie 877 43 8.0 841 6.7 92
T tracycline 97.0 1.5 15 975 10 16
Il-Illclamose pos 5.2% 122
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Table 5 COSI (10 118han L1(o) to Nalionai Heallh Service of parente,al anllb,oliC Irealmenl 01 lower ,espi,olory IraCI IOfeclions In Ihe homa.
oUlpallent and hosp'tal IOpall"nts 501 lings Ill)
Cost hypotheses (1995)
Purchase of nllb,otlcs (Lire)
Materials labor (Lire)



















The whole ale. noncnocal apphcaoon of gUJdeHncs for-
mul.lled 111 other countnc\ constitu[C~, in Ollr 0pl11lon. a
lerious methodological Jnd conceptual error. 1\5 alr<~ady stated.
pCllIcillin re istallce 10 It:llbn ~rrallls of freIJ!Or('rrt/s IlIIermllJlJ;ile
IS r.ue. whereas resl tance to macrolides (31.7% in 199R), to
tctracyclines (32.2%) and to cOlnmoxazole (30.7%) is on the
IIlCrcase. 'Icarly, then. i the dnlg chOICes reconlmended In
the p;U1dehne~ of the Infectious Dlsea. ~ So iety of AmenLl
(lllacrohdL'S. terracycblle<.. new Ouoroql\lnolonc) were
adopted an Ilaly, they \ ould be inappropri<lte in ~vo ca c~
nlllofthree.
( ne ~hould also carefully C()Jl~ldcr the fuct that the therapeuti
amtlldes of h:aban phvsicians [IOJ, often the t:lrgel ofsubsCinnal
cnticlSrtl. both a rcgards the chOIce ofanobIOO(5 (p-JactaJlls and
thIrd-generation cephalosponn5, in pam lIar) alld the adnlln-
15traUon r tile (pan:mcraJ). arc probably respon,lble for the
pr("clI! overall reslstallce patTern. which h very favorahle
compared WIth thaI clH:ountcred III many oth ...r COUlltries.
FurthemlOre. the n:slIl obtained in till' therapy of
cOlllmurmy-acqllired pneul1lonlJ arc better than those of
other European ·ounlrie~. The fallllfc rale in Italy, af1w
ho~pltal rreml1lCJ1l of community-a qUIfl:d pnClIl1l nia, i~ 6%
ofc,\c tre.tedagaimIIO%and 13%in ennanyand the UK.
rl."'\pectlVely ablc -I). he 1ll0rWllY . te ill h.ly r. r I w.:r
respiratory tract infection is (\.8% as compared with 15% in
the UK.
In Italy, re pi I ry IflfeCtlOflS . re Illallily trcarea by general
pr:lctitloners that refer only miru.mal percentage of p tients t
Itmpltal (20/..-3%); In the UK the re erraJ rate for the~e dlsca.,es
IS 9% of ascs.
In th)~ connection, we ~hould re .11 that the me.11l COM to
the altona! Health ystell1 of home parcllIcral ,mibiotl
treatment I -168-225 ire a. compared \ ith 697-151 LIre fot
~1'>ted hOl1le c, re alld .jH5· 266 Lire tor hOSplf' I treatlllem
able 5) 1111.
In the light fall thl'Se findings, \ • arc of Ihe 0plllwn th, I.
n the rrength 0 1111 r bioJo¢c I. Iinical-ther.ll'(·uti and
phamlacOCCOnOl111C n~lderariotl', the rl.·uricnVl: hypOll) ·Sc.s
~ornctlmc, C n1emplated at n jlnstcrial Icvel With rcp;;m!t(l the
USc of bro,d-specrrul11 alltlblOtlcs, slll:h a~. P3rt1CUlariy. tI,c
third-gcneration ccphalo~poril1S, are clearly Iargcl untenable
anJ Inopportune.
p-lacLll1lS and cl'JlhaJo~pl1rin~. til parricu! r, continue [()
pia, a fundament; I role in cl,t: thcrapy of lower re:piratOry
traCt infectlons.
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